Amgen wins patent fight with Roche


Roche's siege on Amgen anemia-drugs territory is ending with a whimper. A jury ruled that the Swiss drug maker's Mircera product infringes three Amgen patents. Short of "evaluating its legal options" in hopes of a valid appeal, there's little Roche can do to fight back now.

Roche had hoped to roll out Mircera in the U.S. this year. Roche has already introduced Mircera in several EU countries; it expects FDA approval for the drug next month. But armed with its validated patents, Amgen now plans to seek an injunction to stop the product Stateside. Mircera would compete with Epogen and Aranesp, which remain Amgen's cash-cow drugs even as debates rage over their safety.

- see Amgen's release

Related Articles:
Amgen flexes for Roche showdown. Report
Amgen, Roche square off. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in U.K. and Germany. Report


Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.